Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility
The new facility includes six classified environment rooms with space to expand.
Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a subsidiary of Hitachi Chemical and the company’s Regenerative Medicine Business Sector (RMBS) representative in North America, has opened its new cell and gene therapy manufacturing facility in Allendale, NJ, HCATS announced on Jan. 30, 2020. The new facility was built from the ground up and more than doubles HCATS’ existing manufacturing capacity in New Jersey.
The facility includes six classified environment rooms and has the capacity to add more rooms that can be specifically configured to accommodate growing client needs. It has state-of-the-art manufacturing development laboratories, quality control and microbiological laboratories, warehousing, executive offices, and meeting space.
“The opening of this new facility marks an important milestone for HCATS and will offer a state-of-the-art resource for our clients as they commercialize cell and gene therapies. Access to this type of manufacturing space is needed across the industry to ensure the continued growth and momentum of these promising therapeutics,” said Robert Preti, PhD, president and CEO, HCATS, and general manager, RMBS, in a company press release. “This facility will require up to 500 more employees to reach full operational capacity over the next several years, supporting our growing roster of clients.”
“I am excited for Hitachi Chemical Advanced Therapeutics Solutions’ future in New Jersey, and I have no doubt that their new, state-of-the-art facility will not only help New Jersey residents, but also contribute to expanding the innovation economy by bringing up to 500 new jobs to our state,” added Governor Phil Murphy of New Jersey in the press release. “With our highly educated and diverse workforce, New Jersey is the perfect location for expanding biotech firms like Hitachi Chemical.”
Hitachi Chemical’s RMBS provides contract development and manufacturing organization (CDMO) services at current good manufacturing practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The business includes operations in North America (Allendale, NJ and Mountain View, CA), Europe (Munich, Germany), and Japan (Yokohama).
Source: Hitachi Chemical
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
